NCT00017394View on ClinicalTrials.gov

Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

September 30, 2007

Conditions
Male Breast CancerRecurrent Breast CancerStage IV Breast Cancer
Interventions
BIOLOGICAL

bevacizumab

Given IV

DRUG

vinorelbine tartrate

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00017394 - Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter